Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash & Equivalents (2021 - 2025)

Bioregenx (BRGX) has 5 years of Cash & Equivalents data on record, last reported at $46947.0 in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 33.01% year-over-year to $46947.0; the TTM value through Sep 2025 reached $46947.0, down 33.01%, while the annual FY2024 figure was $58404.0, 53.43% down from the prior year.
  • Cash & Equivalents reached $46947.0 in Q3 2025 per BRGX's latest filing, up from $46456.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $125402.0 in Q4 2023 and bottomed at $676.0 in Q4 2022.
  • Average Cash & Equivalents over 5 years is $45383.0, with a median of $46701.5 recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: plummeted 97.22% in 2022, then soared 18450.59% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $24358.0 in 2021, then tumbled by 97.22% to $676.0 in 2022, then skyrocketed by 18450.59% to $125402.0 in 2023, then tumbled by 53.43% to $58404.0 in 2024, then decreased by 19.62% to $46947.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $46947.0 in Q3 2025, $46456.0 in Q2 2025, and $83625.0 in Q1 2025.